MGI(SH:688114) 智通财经网·2026-02-27 09:28Core Viewpoint - The company, BGI Genomics, reported significant improvements in its financial performance for the fiscal year 2025, with a notable reduction in losses and a focus on enhancing operational efficiency through various strategic initiatives [1][2]. Financial Performance - BGI Genomics achieved a total revenue of 2.78 billion yuan in 2025, with a narrowed net loss of 237 million yuan, representing a 60.57% year-over-year improvement [1]. - The company's non-recurring net loss was 378 million yuan, which is a 42.11% reduction compared to the previous year [1]. - Operating expenses (excluding financial costs) decreased by approximately 19% year-over-year, indicating improved operational efficiency [1]. Product Development and Market Position - The company launched several key products in 2025, including the T1+ sequencer, which received high industry recognition and saw rapid growth in installation volume [1]. - The T7+ sequencer achieved cost reduction and quality improvement, while the E25 sequencer received NMPA certification and significantly increased sales, expanding into international markets such as Europe and Latin America [1]. - BGI Genomics has captured around 70% of the public tender market share in China for 2025, reflecting its leading position in the industry [1]. Strategic Acquisitions and Technological Advancements - BGI Genomics announced plans to acquire cutting-edge platforms in spatial genomics and nanopore sequencing, positioning itself as a unique player with a comprehensive product matrix in the life sciences sector [2]. - The CycloneSEQ nanopore sequencing technology is now competitive with international leaders, while the Stereo-seq spatial genomics technology surpasses similar products from 10X Genomics [2]. Global Business Expansion and Financial Strategy - The company plans to transfer 100% ownership of its subsidiary Complete Genomics, Inc. for approximately 50 million USD, while upgrading sequencing technology licenses in North America [3]. - This move signifies a transition from "product output" to "technology output," which is expected to enhance financial performance and support global development strategies [3]. - The transaction is anticipated to improve cash flow, reduce annual losses significantly, and solidify long-term revenue streams, thereby enhancing the company's profitability and cash flow quality [3]. Market Trends and Future Outlook - BGI Genomics is positioned to benefit from the explosive growth in the "AI + healthcare" market, leveraging its advanced technologies and dual advantages in life sciences [3]. - The company is expected to shorten the timeline for achieving profitability through its innovative global strategies and efficient resource allocation [3].